Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients

Published:2014-12-23 Issue:4 Volume:6 Page:450-457
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Hu Ming-ming¹,Hu Ying¹,Gao Guang-kuo²,Han Yi³,Shi Guang-li⁴,Li Bao-lan¹

Affiliation:

1. Department of General Medicine; Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital; Capital Medical University; Beijng China

2. Department of Anesthesia; Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital; Capital Medical University; Beijng China

3. Department of Thoracic Surgery; Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital; Capital Medical University; Beijng China

4. Clinical Laboratory; Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital; Capital Medical University; Beijng China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12202/fullpdf

Reference34 articles.

1. Anti-angiogenesis therapies: their potential in cancer management;Eichholz;Onco Targets Ther,2010

2. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies;Shih;Clin Ther,2006

3. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions;Ellis;Crit Rev Oncol Hematol,2012

4. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy;Jain;Science,2005

5. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid;Senger;Science,1983

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib: A Novel Molecular-Targeted Drug for Tumours;Journal of Biomedical Nanotechnology;2023-06-01

2. HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer;Oncology Reports;2020-04-09

3. Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT/MMP‐2/VEGF pathway;Basic & Clinical Pharmacology & Toxicology;2019-08-08

4. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study;International Journal of Clinical Oncology;2018-10-29

5. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation;Oncotarget;2016-09-16